, Volume 23, Supplement 1, pp S15–S20 | Cite as

Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice

  • N. C. Karalus
  • J. E. Garrett
  • S. D. R. Lang
  • R. A. Leng
  • G. N. Kostalas
  • R. T. M. Cursons
  • B. C. Cooper
  • C. J. Ryan


Two hundred and forty-two patients over 16 years of age with community-acquired lower respiratory tract infection (LRTI), matched for age and sex, were randomised to receive either roxithromycin 150 mg b.i.d. or amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for 7 days, with a further 7 days if insufficient response was seen. Clinical efficacy at 7 days was 69% for roxithromycin and 56% for amoxycillin/clavulanic acid (p=0.05) and at study end it was 91% for both antibiotics. There were fewer second treatment courses in the roxithromycin group (26% vs. 38%, p=0.04) and a shorter treatment duration (8.29 days vs. 9.34 days, p>0.05). Twelve patients (9.8%) treated with roxithromycin and 19 (17.1%) treated with amoxycillin/clavulanic acid had adverse effects possibly, or probably, related to the antibiotic. Roxithromycin appears to be a more appropriate choice than amoxycillin/clavulanic acid for the treatment of LRTI in the community given its more appropriatein vitro spectrum, efficacy against most common and atypical pathogens, greater cost-effectiveness, more convenient dosage regimen (b.i.d.), and superior tolerability profile.


Chronic Obstructive Pulmonary Disease Lower Respiratory Tract Infection Clavulanic Acid Roxithromycin Cefaclor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


242 Patienten über 16 Jahre mit einer im ambulanten Bereich erworbenen Infektion der unteren Luftwege, die nach Alter und Geschlecht entsprechend erfaßt wurden, erhielten randomisiert 7 Tage lang zwei mal täglich 150 mg Roxithromycin oder drei mal täglich Amoxycillin 500 mg/Clavulansäure 125 mg. Bei unzureichendem Erfolg noch weitere 7 Tage. Klinisch wirksam erwiesen sich bei Roxithromycin 69% und 56% bei Amoxycillin/Clavulansäure (p=0.05), bei Abschluß der Studie waren es 91% bei beiden Präparaten. Weniger Zweitbehandlungen waren bei der Roxithromycin-Gruppe erforderlich, sowie eine kürzere Behandlungsdauer (8,29 Tage vs. 9,34 Tage, p>0,05). 12 Patienten, die mit Roxithromycin behandelt wurden und 19 Patienten mit Amoxycillin/Clavulansäure hatten Nebenerscheinungen, die möglicherweise oder wahrscheinlich auf die Antibiotika bezogen werden könnten. Roxithromycin erscheint für LRTI im ambulanten Bereich eine geeignetere Behandlung zu sein als Amoxycillin/Clavulansäure. Es erreicht ein breiteresin vitro-Spektrum, eine größere Wirksamkeit gegenüber den vorkommenden Erregern, eine bessere Kosten-Nutzen Relation, eine einfachere Behandlungsform (b.i.d.) sowie eine bessere Verträglichkeit.


  1. 1.
    Lassman, H. B., Puri, S. K., Ho, I., Sabo, R., Mezzino, M. J.: Pharmacokinetics of roxithromycin. J. Clin. Pharmacol. 28 (1988) 141–152.PubMedGoogle Scholar
  2. 2.
    Mac Donald, P.: New approaches to the management of community acquired pneumonia. JAMA 3 (SEA) (Suppl.) (1990) 14–19.Google Scholar
  3. 3.
    Young, R. A., Gonzalez, J. P., Sorkin, E. M.: Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 37 (1989) 8–41.PubMedGoogle Scholar
  4. 4.
    Todd, P. A., Benfield, P.: Amoxycillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39 (1990) 264–307.PubMedCrossRefGoogle Scholar
  5. 5.
    Graham, V. A. L., Lowes, J. A. Shaw, E. J. Davies, R. J. The value of Augmentin in the management of RTI. Augmentin: Proc. Int. Symp., Montreux, Switzerland, July 1981,Leight, D. A. andRobinson, O. P. W. (eds.): Excerpta Medica, pp. 138–148.Google Scholar
  6. 6.
    Bartlett, J. G., Ryan, K. J., Smith, T. F., Wilson, W. R.: The laboratory diagnosis of lower respiratory tract infections. Cumitech 7A. American Society for Microbiology (1987), Washington, D. C., 1987, pp. 1–18.Google Scholar
  7. 7.
    Scott, W. G., Cooper, B. C., Scott, H. M.: Roxithromycin versus amoxycillin/clavulanic acid for community treated lower respiratory tract infection. A pharmacoeconomic study. Infection Suppl. 1 (1995) S21–S24.Google Scholar
  8. 8.
    Dautzenberg, B., Scheimberg, A., Brambilla, C., Camus, P., Godard, P., Guerin, J-C, Lemarie, E., Rezvani, Y., Rosembaum, M., Tuchais, E., Wallaert, B.: Comparison of two oral antibiotics, roxithromycin and amoxycillin plus clavulanic acid, in lower respiratory tract infections. Diagn. Microbiol. Infect. Dis. 15 (1992) 85S-89S.PubMedCrossRefGoogle Scholar
  9. 9.
    Lousbergh, D., Jochems, G., Everaert, L., Puttermans, M.: Roxithromycin versus amoxycillin-clavulanic acid in the treatment of respiratory tract infections. Diagn. Microbiol. Infect. Dis. 15 (1992) 91S-95S.PubMedCrossRefGoogle Scholar
  10. 10.
    Billias, A.: Lower respiratory tract infections. Prim. Care. 17 (1990) 811–824.Google Scholar
  11. 11.
    Dumlay, J., Reinhard, R., Donn Roi, L.: A placebo controlled double-blind study of erythromycin in adults with acue bronchitis. J. Fam. Pract. 25 (1987) 137–141.Google Scholar
  12. 12.
    Brickfield, F. X., Carter, W. H., Johnson, R. E.: Erythromycin in the treatment of acute bronchitis in a community practice. J. Fam. Pract. 23 (1986) 119–122.PubMedGoogle Scholar
  13. 13.
    Franks, P., Gleiner, J. A.: The treatment of acute bronchitis with trimethoprim and sulphamethoxazole. J. Fam. Pract. 19 (1984) 185–190.PubMedGoogle Scholar
  14. 14.
    Anthonisen, N. R., Manfreda, J., Warren, C. P. W., Hershfield, E. S., Harding, G. K. M., Nelson, N. A.: Antiobitic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (1987) 196–204.PubMedGoogle Scholar
  15. 15.
    Lentino, J. R., Lucks, D. A.: Non-value of sputum culture in the management of lower respiratory tract infection. J. Clin. Microbiol. 25 (1987) 758–762.PubMedGoogle Scholar
  16. 16.
    Grayston, J. T.: Infections caused byChlamydia pneumnoniae strain TWAR. Clin. Infect. Dis. 15 (1992) 757–763.PubMedGoogle Scholar
  17. 17.
    Barker, C. E., Sillis, M., Wreghitt, T. G.: Evaluation of Serodia Myco II agglutination test kit for detectingMycoplasma pneumoniae antibody: comparison with μ-capture ELISA and indirect immunoflu-orescence. J. Clinical Pathol. 43 (1990) 163–165.Google Scholar
  18. 18.
    Mandell, G. L., Douglas, R. G., Bennett, J. E.: Principles and practice of infectious disease, 3rd ed. Churchill, London 1990, pp. 531–555.Google Scholar
  19. 19.
    Scott, W. G., Tilvard, M. W., Dovey, S. M., Cooper, B., Scott, H. M.: Roxithromycin versus cefaclor in lower respiratory tract infection. A general practice pharmacoeconomic study. Pharmaco Economics 4 (1993) 122–130.Google Scholar
  20. 20.
    Saito, A.: Bacteriological and clinical evaluation of roxithromycin in pneumonia. JAMA Suppl. 6 (SEA) (1990) 20–23.Google Scholar
  21. 21.
    Neu, H. C., Wilson, A. P. R., Grüneberg, R. N.: Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J. Chemother. 5 (1993) 67–93.PubMedGoogle Scholar
  22. 22.
    De Rose, V., Ferrara, A., Mangiarotti, P., Nonis, A., Bertoletti, R., Gialdroni Grassi, G.: Penetration of roxithromycin into bronchial secretions. Int. J. Pharmacol. Res. 8 (1988) 107–110.Google Scholar
  23. 23.
    Levison, M. E., Santoro, J., Agarwal, B. N.:In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure. Postgrad. Med. J. 55 (Suppl. 4) (1979) 12–16.PubMedGoogle Scholar
  24. 24.
    Simon, C., Gatzemeier, U.: Serum and sputum levels of cefaclor. Postgrad. Med. J. 55 (Suppl. 4) (1970) 30–34.Google Scholar
  25. 25.
    Brogden, R. N., Speight, T. M., Avery, G. S.: Amoxycillin, a review. Drugs 9 (1975), 88–140.Google Scholar
  26. 26.
    Anderson, R., Van Rensburg, C. E. J., Joone, G., Lukev, P. T.: Anin vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromcyin. J. Antimicrob. Chemother. 20 (Suppl. B) (1987) 57–68.PubMedGoogle Scholar
  27. 27.
    Greenberg, R. N.: Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 6 (1984) 592–596.PubMedGoogle Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1995

Authors and Affiliations

  • N. C. Karalus
    • 1
  • J. E. Garrett
    • 2
  • S. D. R. Lang
    • 3
  • R. A. Leng
    • 1
  • G. N. Kostalas
    • 4
  • R. T. M. Cursons
    • 1
  • B. C. Cooper
    • 5
  • C. J. Ryan
    • 6
  1. 1.HamiltonNew Zealand
  2. 2.Greenlane HospitalAucklandNew Zealand
  3. 3.Middlemore HospitalAucklandNew Zealand
  4. 4.Castle HillAustralia
  5. 5.Delpharm Ltd.AucklandNew Zealand
  6. 6.Roussel New ZealandAucklandNew Zealand

Personalised recommendations